Compare AbbVie Inc (ABBV) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Ecolab Inc. — how do they compare? AbbVie Inc trades at $248.44 (market cap $438.19B), while Ecolab Inc. trades at $284.99 (market cap $79.73B). The key difference: AbbVie Inc is far larger — about 5.5× Ecolab Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | ECL | |
|---|---|---|
Market Cap | $438.19B | $79.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $308.35 |
52-Week Low | $197.38 | $245.73 |
Enterprise Value | $502.45B | $88.51B |
Dividend Yield | 2.79% | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.47, up 0.99% with a bullish technical signal supported by moving averages and oversold RSI levels. The company demonstrates strong revenue growth with 2025 revenue reaching $61.16B and consistent earnings beats in recent quarters. Recent positive clinical trial results for ovarian cancer treatment and institutional accumulation signal confidence in the company's pipeline and growth trajectory.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 consensus price target offering 13% upside. Key risks include patent cliffs in the 2030s and high debt levels, but robust immunology portfolio growth and dividend aristocrat status provide stability. The stock's current valuation metrics suggest premium pricing relative to historical levels.
ECL trades at $285.17, up 0.6% today, with a bullish technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 12.57% and robust cash flow from operations of $2.95B in 2025. Recent news highlights dividend declarations and institutional buying interest.
Outlook is positive with a consensus price target of $327.90, implying 15% upside. Risks include elevated valuation multiples and potential margin pressure from input costs. The stock's momentum is supported by earnings beats and strategic acquisitions, but investors should monitor debt levels and competitive dynamics in the water and hygiene sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
